Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Gynecological Endocrinology

• Publication date

  2013-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/09513590.2013.801446PMID 23767831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer.

  2018cited by this paper
• Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma.

  2013cited by this paper
• Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.

  2013cited by this paper
• Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.

  2012cited by this paper
• A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2012cited by this paper
• North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.

  2012cited by this paper
• Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

  2012cited by this paper
• Laparoscopy versus laparotomy for the management of early stage endometrial cancer.

  2012cited by this paper
• Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.

  2012cited by this paper
• AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study

  2012cited by this paper
• A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

  2012cited by this paper
• A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

  2012cited by this paper
• A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

  2012cited by this paper
• Adjuvant radiotherapy for stage I endometrial cancer.

  2012cited by this paper
• Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

  2011cited by this paper
• Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

  2011cited by this paper
• The evolving role of adjuvant therapy in endometrial cancer.

  2011cited by this paper
• Clinical predictors of bevacizumab-associated gastrointestinal perforation.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Endometrial cancer: reviving progesterone therapy in the molecular age.

  2011cited by this paper
• Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

  2011cited by this paper
• Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

  2010influential reference
• Lymphadenectomy for the management of endometrial cancer.

  2010cited by this paper
• Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

  2010cited by this paper
• A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

  2010cited by this paper
• Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib

  2010cited by this paper
• Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.

  2010cited by this paper
• A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.

  2010cited by this paper
• Lymphadenectomy in endometrial cancer – Authors' reply

  2009cited by this paper
• Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

  2009cited by this paper
• Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

  2009cited by this paper
• FGFR2 as a molecular target in endometrial cancer.

  2009cited by this paper
• Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

  2009cited by this paper
• Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

  2008influential reference
• Drug-sensitive FGFR2 mutations in endometrial carcinoma

  2008cited by this paper
• Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia

  2008cited by this paper
• Molecule-targeted agents in endometrial cancer

  2008cited by this paper
• FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

  2008cited by this paper
• Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

  2008influential reference
• The thalidomide saga.

  2007cited by this paper
• Endometrial carcinoma: pathology and genetics.

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells.

  2007cited by this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cited by this paper
• Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

  2007cited by this paper
• Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

  2007cited by this paper
• Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer

  2007cited by this paper
• Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

  2006cited by this paper
• Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.

  2005cited by this paper
• Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.

  2005cited by this paper
• VEGF and Its Receptors (flt-1 and KDR/flk-1) as Prognostic Indicators in Endometrial Carcinoma

  2005cited by this paper
• Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper
• Oncogenic kinase signalling

  2001cited by this paper
• The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma

  2001cited by this paper
• Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

  2001cited by this paper
• Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma.

  2001cited by this paper
• Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival.

  2001cited by this paper
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

  2000cited by this paper
• Clinical Studies

  1877cited by this paper

• Advancements in Endometrial Cancer Research in 2024

  2025cites this paper
• Advancements in Endometrial Cancer Research in 2023

  2024cites this paper
• Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway

  2024cites this paper
• Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal–Maternal Interface

  2020cites this paper
• Variances in the level of of COX-2 and iNOS in different grades of endometrial cancer.

  2019cites this paper
• Targeting fibroblast growth factor pathways in endometrial cancer.

  2017cites this paper
• Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature

  2017cites this paper
• Dovitinib (TKI258) - A Novel Therapeutic Option in Advanced-Stage Endometrial Cancer?

  2016cites this paper
• An update on the current pharmacotherapy for endometrial cancer

  2016cites this paper
• PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies.

  2016cites this paper
• PET Imaging Toward Individualized of Urologic and Gynecologic Malignancies

  2016cites this paper
• Neutrophils: important contributors to tumor progression and metastasis

  2015cites this paper
• Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.

  2015cites this paper
• Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.

  2014cites this paper